Highlights

  • Bell Potter issued buy ratings on WRK, AV1, and MVP with targets ranging from AUD 0.16 to AUD 0.84.
  • MVP and AV1 reported higher revenue metrics and maintained cash balances above AUD 6 million.
  • WRK outlined platform delivery milestones and an expanding pipeline across multiple client segments.

The ASX small-cap segment has shown a different performance profile compared with larger listed companies over the past year. As of 5 February, the S&P/ASX Small Ordinaries Index (XSO) was trading at 3,716.10, down 74.30 points (1.96%) on the day, while recording a gain of over 15% on a one-year basis. In comparison, the S&P/ASX 200 Index (XJO) closed at 8,889.20, lower by 38.60 points (0.43%), with a 5.61% rise over the same period. The contrasting index movements highlight differing market dynamics across company size segments.

Against this backdrop, broker activity within the ASX small-cap space has continued, with Bell Potter issuing buy ratings on selected stocks following recent company updates and valuation assessments.

Bell Potter Securities has issued buy ratings on three ASX-listed small-cap stocks - WRKR Ltd (ASX:WRK), Adveritas Ltd (ASX:AV1), and Medical Developments International Ltd (ASX:MVP). The ratings were accompanied by target prices that sit above recent trading levels.

Bell Potter Buy Calls and Target Prices

Bell Potter initiated or maintained buy ratings across the three small-cap names. WRK was assigned a target price of AUD 0.16, while AV1 received a target price of AUD 0.22. MVP was given a buy rating with a target price of AUD 0.84.

As of 5 February, WRK shares traded at AUD 0.15, AV1 at AUD 0.099, and MVP at AUD 0.46, placing all three below Bell Potter’s stated valuation levels.

MVP Reports Revenue Growth and Cash Position

Medical Developments International released its quarterly update on 30 January, reporting positive cashflow from operating activities for the first half of FY26. Penthrox revenue increased by AUD 2.3 million, with Australian hospital segment volumes rising 26%.

European in-market Penthrox volumes grew 10%, while progress continued on regulatory approvals for the paediatric label in Europe. During the quarter, the MAGPIE paediatric study was published in Injury. The company reported a cash balance of AUD 16.9 million as at 31 December 2025.

AV1 Posts Higher Recurring Revenue

Adveritas released its December 2025 quarterly update on 21 January, reporting annualised recurring revenue of AUD 14.25 million, up 17% from the prior quarter. Cash receipts from customers totalled AUD 3.2 million, representing growth compared with both the September 2025 and December 2024 quarters.

The company continued investment in product development, including artificial intelligence capabilities, alongside progress in the US market. Adveritas reported a cash balance of AUD 6.85 million at 31 December 2025.

WRK Highlights Platform Development and Pipeline

WRKR released its quarterly update on 29 January, reporting cash receipts of AUD 3.2 million for the quarter. Revenue was supported by feature development under MUFG agreements, ongoing Beam Platform development, and recurring income from Wrkr PAY transactions.

Operating payments rose to AUD 3.8 million in Q2 FY26 from AUD 3.4 million in the prior quarter. WRKR also outlined progress across boutique fund implementations and an expanding ERP pipeline linked to upcoming API releases scheduled for March.

Bell Potter’s buy ratings on WRK, AV1, and MVP might followed recent quarterly updates that detailed revenue activity, product development, and cash positions. With all three stocks trading below their respective target prices as of early February, the broker’s assessments placed these ASX small caps under market focus.

 

FAQ Section

Q1: Which ASX small-cap stocks received Bell Potter buy ratings?
Bell Potter issued buy ratings on WRKR Ltd (WRK), Adveritas Ltd (AV1), and Medical Developments International (MVP).

Q2: What target price did Bell Potter set for MVP?
Bell Potter set a target price of AUD 0.84 for MVP.

Q3: When were the latest quarterly updates released?
MVP released its update on 30 January, AV1 on 21 January, and WRK on 29 January.